Targovax ASA ended 2017 with a cash balance of NOK 261.6 million (€27.1 million), aided by a capital increase in the third quarter, which enabled the company to sustain heavy investments in its oncolytic virus and peptide vaccine platforms. ---Subscribe to MedNous to access this article--- Company News
